Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 4c; Boosts FY13 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Jefferies Raises Numbers on Myriad Genetics (MYGN)
November 6, 2012 12:54 PM ESTJefferies maintained a Buy rating on Myriad Genetics (NASDAQ: MYGN) and raised its price target to $33.00 (from $31.00). Myriad recently reported earnings that were ahead of consensus, and as a result analysts raised EPS estimates on the diagnostics company.
"We expect... More
